Piramal Pharma trades lower by over 2% after Q1 earnings
EBITDA margin for the June quarter grew to 10 percent up from 6 percent in Q1FY23.04-08-2023
04-08-2023
Q1FY24 Quarterly Result Announced for Piramal Pharma Ltd.
Pharmaceuticals company Piramal Pharma announced Q1FY24 results: Revenue from operation of Rs 1,749 crore in Q1FY24 compared to Rs 1,482 crore, up 18% YoY EBITDA of Rs 171 crore in Q1FY24 compared to Rs 89 crore in Q1FY23, up 92% YoY EBITDA margin of 10% in Q1FY24 compared to 6% in Q1FY23 PAT of Rs (99) crore in Q1FY24 compared to Rs (109) crore in Q1FY23 The company has shared the details of its Rights Issue - Rights Price of Rs 81, Record Date of August 2, 2023, and Entitlement Ratio of 5:46 Nandini Piramal, Chairperson, Piramal Pharma Limited said, “We had a positive start to the new financial year with healthy revenue growth and improvement in our EBITDA margins. Our CDMO business is also witnessing continued order inflows, especially for our differentiated offerings and innovation-related work. Our Inhalation Anesthesia portfolio is seeing a healthy demand and our India Consumer Healthcare business is delivering good growth driven by power brands. We continue to maintain our best-in-class quality track record and are also taking multiple initiatives in the area of ESG to grow our business responsibly. Historically our H2 has been better than H1, both in terms of revenue and profitability. We are working to leverage our good start to the financial year and continuing this momentum to deliver a healthy YoY performance for the rest of the year. We believe in the growth potential of our business and are accordingly executing our strategic priorities to create shareholder value. Our promoter and promoter group have agreed to subscribe to the extent of 100% of the equity shares offered in our Rights Issue, thereby reaffirming their confidence in the underlying strengths of our business.” Result PDF04-08-2023
Piramal Pharma Ltd - 543635 - Compliances-Reg. 54 - Asset Cover details
Security Asset Cover Certificate03-08-2023
Piramal Pharma Ltd - 543635 - Statement Of Deviation And Variation For Quarter Ended 30Th June, 2023
Statement of Deviation and Variation for Quarter Ended 30th June, 202303-08-2023
Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release - Unaudited Financial Results (Standalone and Consolidated) of the Comoany for the quarter ended 30th June, 202303-08-2023
Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Investor Presentation
Press Release and Investor Presenation - Unaudited Financial Results(Standalone and Consolidated) of the company for quarter ended 30th June, 202303-08-2023
Piramal Pharma Ltd - 543635 - Outcome Of The Meeting Of The Board Of Directors Of Piramal Pharma Limited Held On 3Rd August, 2023
Outcome of the Meeting of the Board of Directors of Piramal Pharma Limited held on 3rd August, 202303-08-2023
Piramal Pharma Ltd - 543635 - Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of Piramal Pharma Limited Held On 3Rd August, 2023
Outcome of the Meeting of the Board of Directors of Piramal Pharma Limited held on 3rd August, 202303-08-2023
Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
Ammendment to Articles of Association of the Company.31-07-2023
Piramal Pharma Ltd - 543635 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Proceedings and Scrutinizer''s Report of the 3rd Annual General Meeting of the Company31-07-2023